- Helius, a neurotech business, has rebranded to “Solana Company” to reflect its new digital asset treasury strategy.
- The move comes hot on the heels of Pantera and Summer Capital’s $500 million backing to ultimately transform it into the world’s largest SOL treasury company.
- The SOL-centric rebranding confused investors, raising questions regarding the institution’s new focus.
- However, the medical technology firm’s latest filing with the US FDA confirms it will operate as a DAT alongside its original business.
Helius Medical Technologies, Inc. has completely transitioned to “Solana Company.” The move reflects its new identity as a digital asset treasury (DAT) entity leveraging Solana (SOL). Despite the new name, it retains its HSDT ticker on Nasdaq.
Cooperation Between Solana Company and Solana Foundation
According to a press release on Monday, the business has already filed for an amendment to its Certificate of Incorporation with the Delaware Secretary of State following a board approval on its rebranding. Additionally, it forged a non-binding letter of intent with the Solana Foundation for a strategic collaboration aimed at supporting the growth of the SOL ecosystem.
Aligning with the “Solana By Design” vision, the agreement includes cooperation in on-chain activity, joint initiatives, co-hosting of events, institutional partnership referrals, and other projects linked to Solana. Moreover, it allows Solana Company to purchase SOL tokens from the Solana Foundation at a discount.
Solana Company has Summer Capital and Pantera Capital’s backing, which initially raised $500 million for Private Investment in Public Equity (PIPE) financing. The backers plan to follow it up with another $750 million fundraise through stock warrants. The establishment reportedly wants to position itself as the largest SOL treasury in the world, potentially surpassing Upexi’s 2 million SOL portfolio.
From Helius to Solana Company
Helius focuses on developing non-invasive neurostimulation technology, which aims to enhance nervous system function and the overall health of patients. Its key product is a non-invasive device called “Portable Neuromodulation Stimulator (PoNS)” that delivers subtle electrical stimulation to the tongue to boost brain activity and provide an alternative cure to various neurological conditions.
The rebranding signals a deviation from Helius’ identity as a medical company, which raised confusion among investors and major stakeholders regarding the company’s primary focus. However, the latest developments, like its recent filing with the US Food and Drug Administration (FDA) for PoNS, suggest it’s adopting the SOL-centric treasury strategy alongside its original business.
Solana Company’s failure to issue an official statement on the matter continues to generate an air of uncertainty about its future direction.
